Narcolepsy: A review of evidence for autoimmune diathesis

References

• Aldrich M, Naylor M. Narcolepsy associated with lesions of the diencephalon. Neurology 1989; 39: 1505–1508
   PubMed Web of Science ®Google Scholar
• American Academy of Sleep Medicine. International classification of sleep disorders. American Academy of Sleep Medicine, Westchester, IL 2005, (2nd ed.)
   Google Scholar
• Begovich A, McClure G, Suraj V, Helmuth R, Fildes N, Bugawan T, et al. Polymorphism, recombination, and linkage disequilibrium within the HLA class II region. Journal of Immunology 1992; 148: 249–258
   PubMed Web of Science ®Google Scholar
• Berg O, Hanley J. Narcolepsy in two cases of multiple sclerosis. Acta Neurologica Scandinavica 1963; 39: 252–257
   PubMed Web of Science ®Google Scholar
• Billiard M, Laaberki M, Reygrobellet C, Seignalet J, Brissaud L, Besset A. Elevated antibodies to streptococcal antigens in narcoleptic subjects. Sleep Research 1989; 18: 201
   Google Scholar
• Billiard M, Seignalet J. Extraordinary association between HLA-DR2 and narcolepsy. Lancet 1985; 1: 226–227
   Google Scholar
• Black J, III, Avula R, Walker D, Silber M, Krahn L, Pankratz V, et al. HLA DQB1*0602 positive narcoleptic subjects with cataplexy have CSF IgG reactive to rat hypothalamic protein extract. Sleep 2005; 28: 1191–1192
   PubMed Web of Science ®Google Scholar
• Black J, Krahn L, Pankratz V, Silber M. Search for neuron-specific and non-neuron-specific antibodies in narcoleptic patients with and without HLA DQB1*0602. Sleep 2002; 25: 719–723
   PubMed Web of Science ®Google Scholar
• Black J, Silber M, Krahn L, Fredrickson P, Pankratz V, Avula R, et al. Analysis of hypocretin (orexin) antibodies in patients with narcolepsy. Sleep 2005; 28: 427–431
   PubMed Web of Science ®Google Scholar
• Castillo P, Mignot E, Woodruff B, Boeve B. Undetectable CSF hypocretin-1 in ‘Hashimoto's encephalopathy’ associated with coma. Neurology May, 2004; 1909
   Google Scholar
• Chemelli R, Willie J, Sinton C, Elmquist J, Scammell T, Lee C, et al. Narcolepsy in orexin knockout mice: Molecular genetics of sleep regulation. Cell 1999; 98: 437–451
   PubMed Web of Science ®Google Scholar
• Dale R, Federman D. SAM CD: A comprehensive knowledge base of internal medicine. Scientific American, New York 1997
   Google Scholar
• Dauvilliers Y, Carlander B, Molinari N, Desautels A, Okun M, Tafti M, et al. Month of birth as a risk factor for narcolepsy. Sleep 2003; 26: 663–665
   PubMed Web of Science ®Google Scholar
• Dauvilliers Y, Carlander B, Rivier F, Touchon J, Tafti M. Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset. Annals of Neurology 2004; 56: 905–908
   PubMed Web of Science ®Google Scholar
• Daynes R, Araneo B, Ershler W, Maloney C, Li G, Ryu S. Altered regulation of IL-6 production with normal aging. Possible linkage to the age-associated decline in dehydroepiandrosterone and its sulfated derivative. Journal of Immunology 1993; 150: 5219–5230
   PubMed Web of Science ®Google Scholar
• Dolenc-Grosel L, Vodusek D. The importance of HLA DQB1*0602 typing in Slovene patients with narcolepsy. Cellular & Molecular Biology Letters 2002; 7: 359–360
   PubMed Web of Science ®Google Scholar
• Ekbom K. Familial multiple sclerosis associated with narcolepsy. Archives of Neurology 1966; 15: 337–344
   PubMedGoogle Scholar
• Ellis M, Hetisimer A, Ruddy D, Hansen S, Kronmal G, McClelland E, et al. HLA class II haplotype and sequence analysis support a role for DQ in narcolepsy. Immunogenetics 1997; 46: 410–417
   PubMed Web of Science ®Google Scholar
• Erlich S, Itabashi H. Narcolepsy: A neuropathologic study. Sleep 1986; 9: 126–132
   PubMed Web of Science ®Google Scholar
• Ettinger R, Kwok W. A peptide binding motif for HLA-DQA1*0102/DQB1*0602, the class II MHC molecule associated with dominant protection in insulin-dependent diabetes mellitus. Journal of Immunology 1998; 160: 2365–2373
   PubMed Web of Science ®Google Scholar
• Fernandez-Vina M, Gao X, Moraes M, Moraes J, Salatiel I, Miller S, et al. Alleles at four HLA class II loci determined by oligonucleotide hybridization and their associations in five ethnic groups. Immunogenetics 1991; 34: 299–312
   PubMed Web of Science ®Google Scholar
• Fredrikson S, Carlander B, Billiard M, Link H. CSF immune variables in patients with narcolepsy. Acta Neurologica Scandinavica 1990; 81: 253–254
   PubMed Web of Science ®Google Scholar
• Gencik M, Dahmen N, Wieczorek S, Kasten M, Bierbrauer J, Anghelescu I, et al. A prepro-orexin gene polymorphism is associated with narcolepsy. Neurology 2001; 56: 115–117
   PubMed Web of Science ®Google Scholar
• Gledhill R, Bartel P, Yoshida Y, Nishino S, Scammell T. Narcolepsy caused by acute disseminated encephalomyelitis. Archives of Neurology 2004; 61: 758–760
   PubMedGoogle Scholar
• Goldsby R, Kindt T, Osborne B, Kuby J. Major histocompatibility complex. Immunology, J Noe, M Ryan, K Mergen, G Hadler, A Kudlacik. W.H. Freeman and Company, New York 2003; 161–184
   Google Scholar
• Hara J, Beuckmann C, Nambu T, Willie J, Chemelli R, Sinton C, et al. Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron 2001; 30: 345–354
   PubMed Web of Science ®Google Scholar
• Hecht M, Lin L, Kushida C, Umetsu D, Taheri S, Einen M, et al. Report of a case of immunosuppression with prednisone in an 8-year-old boy with an acute onset of hypocretin-deficiency narcolepsy. Sleep 2003; 26: 809–810
   PubMed Web of Science ®Google Scholar
• Hinze-Selch D, Wetter T, Zhang Y, Lu H, Albert E, Mullington J, et al. In vivo andin vitro immune variables in patients with narcolepsy and HLA-DR2 matched controls. Neurology 1998; 50: 1149–1152
   PubMed Web of Science ®Google Scholar
• Honda Y, Asaka A, Tanimura M, Furusho T. A genetic study of narcolepsy and excessive daytime sleepiness in 308 families with a narcolepsy or hypersomnia proband. Sleep/wake disorders: Natural history, epidemiology and long-term evolution, C Guilleminault, E Lugarcsi. Raven Press, New York 1983; 187–199
   Google Scholar
• Hungs M, Lin L, Okun M, Mignot E. Polymorphisms in the vicinity of the hypocretin/orexin are not associated with human narcolepsy. Neurology 2001; 57: 1893–1895
   PubMed Web of Science ®Google Scholar
• Juji T, Satake M, Honda Y, Doi Y. HLA antigens in Japanese patients with narcolepsy. All the patients were DR2 positive. Tissue Antigens 1984; 24: 316–319
   PubMed Web of Science ®Google Scholar
• Kato T, Honda M, Kuwata S, Juji T, Kunugi H, Nanko S, et al. Novel polymorphism in the promoter region of the tumor necrosis factor alpha gene: No association with narcolepsy. American Journal of Medical Genetics 1999; 88: 301–304
   PubMed Web of Science ®Google Scholar
• Krahn L, Pankratz V, Oliver L, Boeve B, Silber M. Hypocretin (orexin) levels in cerebrospinal fluid of patients with narcolepsy: Relationship to cataplexy and HLA DQB1 status. Sleep 2002; 25: 733–736
   PubMed Web of Science ®Google Scholar
• Lagrange A, Blaivas M, Gomez-Hassan D, Malow B. Rasmussen's syndrome and new-onset narcolepsy, cataplexy, and epilepsy in an adult. Epilepsy & Behavior 2003; 4: 788–792
   PubMed Web of Science ®Google Scholar
• Landolfi J, Nadkarni M. Paraneoplastic limbic encephalitis and possible narcolepsy in a patient with testicular cancer: Case study. Neuro-Oncology 2003; 5: 214–216
   PubMed Web of Science ®Google Scholar
• Langdon N, Welch K, van Dam M, Vaughn R, Parkes D. Genetic markers in narcolepsy. Lancet 1984; 2: 1178–1180
   PubMed Web of Science ®Google Scholar
• Lecendreux M, Maret S, Bassetti C, Mouren M, Tafti M. Clinical efficacy of high-dose intravenous immunoglobulins near the onset of narcolepsy in a 10-year-old boy (letter). Journal of Sleep Research 2003; 12: 347–348
   PubMed Web of Science ®Google Scholar
• Lennon V. The case for a descriptive generic nomenclature: Clarification of immunostaining criteria for PCA-1, ANNA-1, and ANNA-2 auto-antibodies (letter). Neurology 1994; 44: 2412–2415
   PubMed Web of Science ®Google Scholar
• Lin L, Faraco J, Li R, Kadotani H, Rogers W, Lin X, et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999; 98: 365–376
   PubMed Web of Science ®Google Scholar
• Lock C, So A, Welsh K, Parkes J, Trowsdale J. MHC class II sequences of an HLA-DR2 narcoleptic. Immunogenetics 1988; 27: 449–455
   PubMed Web of Science ®Google Scholar
• MacKay I. Autoimmune disease. Annals of General Practice 1971; 68: 68–74
   Google Scholar
• Malik S, Boeve B, Krahn L, Silber M. Narcolepsy associated with other central nervous system disorders. Neurology 2001; 57: 539–541
   PubMed Web of Science ®Google Scholar
• Matsuki K, Honda Y, Naohara T, Satake M, Someya T, Harada S, et al. Lymphocyte subsets in HLA-DR2-positive narcoleptic patients. Folia Psychiatrica et Neurologica Japonica 1985; 39: 499–505
   PubMedGoogle Scholar
• Mieda M, Willie J, Hara J, Sinton C, Sakurai T, Yanagisawa M. Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice. Proceedings of the National Academy of Sciences of the United States of America 2004; 101: 4649–4654
   PubMed Web of Science ®Google Scholar
• Mignot E. Genetic and familial aspects of narcolepsy. Neurology 1998; 50: S16–S22
   PubMed Web of Science ®Google Scholar
• Mignot E, Hayduk R, Black J, Grumet F, Guilleminault C. HLA DQB1*0602 is associated with cataplexy in 509 narcoleptic patients. Sleep 1997; 20: 1012–1020
   PubMed Web of Science ®Google Scholar
• Mignot E, Lin L, Rogers W, Honda Y, Qiu X, Lin X, et al. Complex HLA-DR and -DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups. American Journal of Human Genetics 2001; 68: 686–699
   PubMed Web of Science ®Google Scholar
• Mignot E, Lin X, Arrigoni J, Macaubas C, Olive F, Hallmayer J, et al. DQB1*0602 and DQA1*Q102 (DQ1) are better markers than DR2 for narcolepsy in Caucasian and Black Americans. Sleep 1994; 17: S60–S67
   PubMed Web of Science ®Google Scholar
• Montplaisir J, Poirier G, Lapierre O, Montplaisir S. Streptococcal antigens in narcolepsy and ideopathic hypersomnia. Sleep Research 1989; 18: 271
   Google Scholar
• Mueller-Eckhardt G, Meier-Ewart K, Schiefer H. Is there an infectious origin of narcolepsy? (Letter). Lancet 1990; 335: 424
   PubMed Web of Science ®Google Scholar
• Nishino S, Kanbayashi T, Fujiki N, Uchino M, Ripley B, Watanabe M, et al. CSF hypocretin levels in Guillain-Barre syndrome and other inflammatory neuropathies. Neurology 2003; 61: 823–825
   PubMed Web of Science ®Google Scholar
• Nishino S, Ripley B, Overeem S, Lammers G, Mignot E. Hypocretin (orexin) deficiency in human narcolepsy (letter). Lancet 2000; 355: 39–40
   PubMed Web of Science ®Google Scholar
• Nishino S, Ripley B, Overeem S, Nevsimalova S, Lammers G, Vankova J, et al. Low cerebrospinal fluid hypocretin (orexin) and altered energy homeostasis in human narcolepsy. Annals of Neurology 2001; 50: 381–388
   PubMed Web of Science ®Google Scholar
• Okun M, Giese S, Lin L, Einen M, Mignot E, Coussons-Read M. Exploring the cytokine and endocrine involvement in narcolepsy. Brain, Behavior, & Immunity 2004; 18: 326–332
   PubMed Web of Science ®Google Scholar
• Olafsdottir B, Rye D, Scammell T, Matheson J, Stefansson K, Gulcher J. Polymorphisms in hypocretin/orexin pathway genes and narcolepsy. Neurology 2001; 57: 1896–1899
   PubMed Web of Science ®Google Scholar
• Overeem S, Dalmau J, Bataller L, Nishino S, Mignot E, Verschuuren J, et al. Hypocretin-1 CSF levels in anti-Ma2 associated encephalitis. Neurology 2004; 62: 138–140
   PubMed Web of Science ®Google Scholar
• Overeem S, Geleijns K, Garssen M, Jacobs B, van Doorn P, Lammers G. Screening for anti-ganglioside antibodies in hypocretin-deficient human narcolepsy. Neuroscience Letters 2003; 341: 13–16
   PubMed Web of Science ®Google Scholar
• Overeem S, Scammell T, Lammers G. Hypocretin/orexin and sleep: Implications for the pathophysiology and diagnosis of narcolepsy. Current Opinion in Neurology 2002; 15: 739–745
   PubMed Web of Science ®Google Scholar
• Parkes J, Welsh K, Langdon N, Lock C. Immune factors in narcolepsy in the United Kingdom. HLA in Narcolepsy, Y Honda, T Juji. Springer-Verlag, Berlin 1988; 158–171
   Google Scholar
• Peyron C, Faraco J, Rogers W, Ripley B, Overeem S, Charnay Y, et al. A mutation in early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nature Medicine 2000; 6: 991–997
   PubMed Web of Science ®Google Scholar
• Pittock S, Kryzer T, Lennon V. Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. Annals of Neurology 2004; 56: 715–719
   PubMed Web of Science ®Google Scholar
• Poirier G, Montplaisir J, Decary F, Momege D, Lebrun A. HLA antigens in narcolepsy and idiopathic central nervous system hypersomnolence. Sleep 1986; 9: 153–158
   PubMed Web of Science ®Google Scholar
• Rogers A, Mehan J, Guilleminault C, Grumet F, Mignot E. HLA DR15 (DR2) and DQB1*0602 typing studies in 188 narcoleptic patients with cataplexy. Neurology 1997; 48: 1550–1556
   PubMed Web of Science ®Google Scholar
• Rogers S, Andrews P, Gahring L, Whisenand T, Cauley K, Crain B, et al. Auto-antibodies to glutamate receptor GluR3 in Rasmussen's encephalitis. Science 1994; 265: 648–651
   PubMed Web of Science ®Google Scholar
• Rubin R, Hajdukovich R, Mitler M. HLA-DR2 association with excessive somnolence in narcolepsy does not generalize to sleep apnea and is not accompanied by systemic autoimmune abnormalities. Clinical Immunology and Immunopathology 1988; 49: 149–158
   PubMedGoogle Scholar
• Schrader H, Gotlibsen O, Skomedal G. Multiple sclerosis and narcolepsy/cataplexy in a monozygotic twin. Neurology 1980; 30: 105–108
   PubMed Web of Science ®Google Scholar
• Siebold C, Hansen B, Wyer J, Harlos K, Esnouf R, Svejgaard A, et al. Crystal structure of HLA-DQ0602 that protects against type 1 diabetes and confers strong susceptibility to narcolepsy. Immunology 2004; 101: 1999–2004
   Google Scholar
• Silber M, Krahn L, Olson E. Diagnosing narcolepsy: Validity and reliability of new diagnostic criteria. Sleep Medicine 2002; 3: 109–113
   PubMed Web of Science ®Google Scholar
• Singh S, George C, Ott R, Rattazzi C, Guilleminault C, Dement W, et al. IgH (mu-switch and gamma-1) region restriction fragment length polymorphism in human narcolepsy. Journal of Clinical Immunology 1996; 16: 208–215
   PubMed Web of Science ®Google Scholar
• Smith A, Jackson M, Neufing P, McEvoy R, Gordon T. A functional autoantibody in narcolepsy. Lancet 2004; 364: 2122–2124
   PubMed Web of Science ®Google Scholar
• Strohmaier P, Mueller-Eckhardt G, Meier-Ewert K. Cellular approach for detecting narcolepsy-specific alterations in DR2 haplotypes. Human Immunology 1988; 22: 221–225
   PubMed Web of Science ®Google Scholar
• Taheri S, Krempetz M, Jackson M, Paterno J, Mignot E. Investigation of the autoimmune basis of narcolepsy using western blot analysis of lateral hypothalamus protein extract with serum and cerebrospinal fluid (CSF) (abstract). Sleep 2003; 26: A285
   PubMed Web of Science ®Google Scholar
• Taheri S, Mignot E. The genetics of sleep disorders. Lancet Neurology 2002; 1: 242–250
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Mori H, Mishina M, Watanabe M, Fujiwara T, Shimomura J, et al. Autoantibodies to NMDA receptor in patients with chronic forms of epilepsia partialis continua. Neurology 2003; 61: 891–896
   PubMed Web of Science ®Google Scholar
• Thannickal T, Moore R, Nienhuis R, Ramanathan L, Gulyani S, Aldrich M, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000; 27: 469–474
   PubMed Web of Science ®Google Scholar
• Thannickal T, Siegel J, Nienhuis R, Moore R. Pattern of hypocretin (orexin) soma and axon loss, and gliosis, in human narcolepsy. Brain Pathology 2003; 13: 340–351
   PubMed Web of Science ®Google Scholar
• Thompson M, Comings D, Abu-Ghazalah R, Jereseh Y, Lin L, Wade J, et al. Variants of the orexin2/hcrt2 receptor gene identified in patients with excessive daytime sleepiness and patients with Tourette's syndrome comorbidity. American Journal of Medical Genetics 2004; 129B: 69–75
   PubMed Web of Science ®Google Scholar
• Uryu N, Maeda M, Nagata Y, Matsuki K, Juji T, Honda Y, et al. No difference in the nucleotide sequence of the DQ beta 1 domain between narcoleptic and healthy individuals with DR2, Dw2. Human Immunology 1989; 24: 175–181
   PubMed Web of Science ®Google Scholar
• Vgontzas A, Chrousos G. Sleep, the hypothalamic-pituitary-adrenal axis, and cytokines: Multiple interactions and disturbances in sleep disorders. Endocrinology and Metabolism Clinics of North America 2002; 31: 15–36
   PubMed Web of Science ®Google Scholar
• Vgontzas A, Papanicolaou D, Bixler E, Kales A, Tyson K, Chrousos G. Elevation of plasma cytokines in disorders of excessive daytime sleepiness: Role of sleep disturbance and obesity. Journal of Clinical Endocrinology & Metabolism 1997; 82: 1313–1316
   PubMed Web of Science ®Google Scholar
• Wieczorek S, Dahmen N, Jagiello P, Epplen J, Gencik M. Polymorphisms of the tumor necrosis factor receptors: No association with narcolepsy in German patients. Journal of Molecular Medicine 2003a; 81: 87–90
   PubMed Web of Science ®Google Scholar
• Wieczorek S, Gencik M, Rujescu D, Tonn P, Giegling I, Epplen J, et al. TNFA promoter polymorphisms and narcolepsy. Tissue Antigens 2003b; 61: 437–442
   PubMedGoogle Scholar
• Wieczorek S, Jagiello P, Arning L, Dahmen N, Epplen J. Screening for candidate gene regions in narcolepsy using a microsatellite based approach and pooled DNA. Journal of Molecular Medicine 2004; 82: 696–705
   PubMed Web of Science ®Google Scholar
• Younger D, Pedley T, Thorpy M. Multiple sclerosis and narcolepsy: Possible similar genetic susceptibility. Neurology 1991; 41: 447–448
   PubMed Web of Science ®Google Scholar
• Yu Z, Lennon V. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. New England Journal of Medicine 1999; 340: 227–228
   PubMed Web of Science ®Google Scholar
• Zuberi S, Mignot E, Ling L, McArthur I. Variable response to intravenous immunoglobulin therapy in childhood narcolepsy 13. 2004, 828. European Sleep Research Society
   Google Scholar